Search results
-
New Roche/Poseida project isn’t P-BCMACD19-ALLO1
… of which yielded confounding multiple myeloma data at ASH 2023 ; the dataset now stands at 72 patients, with an …
- 10/22/2024 - 13:43 -
Xencor “still committed” to oncology
… acute leukaemia & T-cell lymphoblastic leukaemia Data at ASH 2023, 2/12 CRs; no longer listed in pipeline …
- 09/10/2024 - 08:01 -
Front-line setting next for axatilimab
… Ph2 Agave-201, monotherapy Approved in US, data at ASH 2023 First line Ph2 Jakafi combo …
- 08/15/2024 - 13:37 -
EHA 2024 preview – Novartis doubles up
… Anti-BCMA Car-T S207 Ph1 results, last updated at ASH 2023 Bristol Myers Squibb Golcadomide … Nurix NX-5948 BTK degrader S155 Had data at ASH 2023 BeiGene BGB-16673 BTK degrader S157 Had data at ASH 2023 Kymera KT-333 Stat3 degrader …
- 05/20/2024 - 18:11 -
Innate gets a new lacutamab blow
… KIR3DL2 expressing) Ph2 Tellomak Final data at ASH 2023: 38% ORR in 56 pts Innate to submit Sézary and …
- 03/21/2024 - 15:43 -
Takeda ploughs a lonely CD38 furrow
… Biosciences China ph2 * uncontrolled trial, data at ASH 2023; China ph2 * placebo-controlled trial completes …
- 06/24/2024 - 11:58 -
After Dreamm-7, how about more multiple myeloma conjugates?
… Pharma/ Huadong Medicine $20m Asia deal; ph1 data at ASH 2023, 0% ORR in 12 patients Ispectamab …
- 02/13/2024 - 14:31 -
Gilead deals more checkpoint disappointment
… HLA-G-targeting CIR-NK cells Preclinical data at SITC & ASH 2023 AR087 Y Biologics Anti-HLA-G MAb …
- 02/12/2024 - 10:40 -
A cancer pipeline cull from AbbVie
… the latter, also on top of Jakafi, didn’t impress at ASH 2023. And the SHP inhibitor JAB-3312, originated by …
- 02/06/2024 - 13:49 -
Car-T comes full circle
… (10/50 pts) in ph1/2 Transcend CLL 004 *, presented at ASH 2023 GLPG5201 Galapagos Autologous … 57% CRR (8/14 pts) in ph1 portion, presented at ASH 2023 Cemacabtagene ansegedleucel Allogene … recent data from the Transcend CLL 004 trial, presented at ASH 2023, showed a 20% complete response rate among a …
- 01/19/2024 - 16:00
